Lauren W. Roth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lauren W. Roth has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Alex J. Polotsky
Divisions of Reproductive Endocrinology and Infertility (L.W.R., J.L., J.C., A.J.P., N.S.), Aurora, Colorado 80045
4 shared publicationsJennifer Lesh
Divisions of Reproductive Endocrinology and Infertility (L.W.R., J.L., J.C., A.J.P., N.S.), Aurora, Colorado 80045
3 shared publicationsNanette Santoro
Divisions of Reproductive Endocrinology and Infertility (L.W.R., J.L., J.C., A.J.P., N.S.), Aurora, Colorado 80045
3 shared publicationsAmanda A. Allshouse
Biostatistics and Informatics (A.A.A.), University of Colorado, Aurora, Colorado 80045
2 shared publicationsAndrew P. Bradford
Basic Reproductive Sciences (A.P.B.), Aurora, Colorado 80045
2 shared publicationsJustin Chosich
Divisions of Reproductive Endocrinology and Infertility (L.W.R., J.L., J.C., A.J.P., N.S.), Aurora, Colorado 80045
2 shared publications
Latest Publications
- Open Access
- 1 May 2014
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 99 (5) , E871-E875
Evidence of GnRH Antagonist Escape in Obese Women
Context: Assisted reproductive technology (ART) cycle cancelation rates are increased among overweight and obese women; however, the reasons for this are not completely clear. Premature luteinization due to inadequate endogenous gonadotropin suppression is a possibility for this higher risk of cancellation. Objective: The objective of the study was to investigate the impact of female obesity on the pharmacokinetics of cetrorelix (GnRH antagonist). Design: This was an interventional study. Setting: The study was conducted at a university clinical and translational research center. Participants: Regularly menstruating obese (n = 10) and normal-weight (n = 10) women participated in the study. Interventions: A frequent blood sampling study was performed after a GnRH antagonist was administered, followed by recombinant LH. Main Outcomes Measured: Pharmacokinetics of cetrorelix in obese vs normal weight women were measured. Results: Five of the obese women (50%) and none of the normal-weight women had a rebound of LH (defined as >50% increase in LH level from nadir) over the 14-hour postdose observation period. The obese group had a significantly decreased distributional half-life of cetrorelix compared with the normal-weight group (8.1 ± 1.6 vs 12.7 ± 6.2 hours, P = .02). The obese group exhibited increased clearance of cetrorelix compared with the normal-weight group (25.8 ± 6.8 vs 20.1 ± 8.3 L/h, P = .058). Conclusions: The altered pharmacokinetics of cetrorelix in obese women may lead to premature ovulation during ART, and this could be one of the mechanisms that results in increased cycle cancelation in this group of women. In accordance with the higher gonadotropin requirements for obese women undergoing ART, weight-based dosing of GnRH antagonists may be required.
- 1 May 2014
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 99 (5) , E871-E875
Open AccessEvidence of GnRH Antagonist Escape in Obese Women
Context: Assisted reproductive technology (ART) cycle cancelation rates are increased among overweight and obese women; however, the reasons for this are not completely clear. Premature luteinization due to inadequate endogenous gonadotropin suppression is a possibility for this higher risk of cancellation. Objective: The objective of the study was to investigate the impact of female obesity on the pharmacokinetics of cetrorelix (GnRH antagonist). Design: This was an interventional study. Setting: The study was conducted at a university clinical and translational research center. Participants: Regularly menstruating obese (n = 10) and normal-weight (n = 10) women participated in the study. Interventions: A frequent blood sampling study was performed after a GnRH antagonist was administered, followed by recombinant LH. Main Outcomes Measured: Pharmacokinetics of cetrorelix in obese vs normal weight women were measured. Results: Five of the obese women (50%) and none of the normal-weight women had a rebound of LH (defined as >50% increase in LH level from nadir) over the 14-hour postdose observation period. The obese group had a significantly decreased distributional half-life of cetrorelix compared with the normal-weight group (8.1 ± 1.6 vs 12.7 ± 6.2 hours, P = .02). The obese group exhibited increased clearance of cetrorelix compared with the normal-weight group (25.8 ± 6.8 vs 20.1 ± 8.3 L/h, P = .058). Conclusions: The altered pharmacokinetics of cetrorelix in obese women may lead to premature ovulation during ART, and this could be one of the mechanisms that results in increased cycle cancelation in this group of women. In accordance with the higher gonadotropin requirements for obese women undergoing ART, weight-based dosing of GnRH antagonists may be required.
- 7 March 2014
- Vol. 59, 87-9
Pregnancy in a woman with premature ovarian insufficiency associated with blepharophimosis, ptosis, epicanthus inversus syndrome type I. A case report.
Blepharophimosis, ptosis, epicanthus inversus syndrome (BPES) type I is a rare disorder that causes a recognizable pattern of eye abnormalities and is associated with premature ovarian insufficiency. There is no data to guide the treatment of these patients when presenting with infertility. A 30-year-old, nulligravid woman with premature ovarian insufficiency associated with BPES type I presented to care secondary to a desire to conceive. Ovarian stimulation with gonadotropins was performed, and the patient conceived and delivered viable twins. It is not known whether premature ovarian insufficiency associated with BPES type I follows the same clinical course as idiopathic premature ovarian insufficiency. In patients with BPES type I who present with infertility, ovarian stimulation with gonadotropins may be a reasonable therapeutic option.
- 7 March 2014
- Vol. 59, 87-9
Pregnancy in a woman with premature ovarian insufficiency associated with blepharophimosis, ptosis, epicanthus inversus syndrome type I. A case report.
Blepharophimosis, ptosis, epicanthus inversus syndrome (BPES) type I is a rare disorder that causes a recognizable pattern of eye abnormalities and is associated with premature ovarian insufficiency. There is no data to guide the treatment of these patients when presenting with infertility. A 30-year-old, nulligravid woman with premature ovarian insufficiency associated with BPES type I presented to care secondary to a desire to conceive. Ovarian stimulation with gonadotropins was performed, and the patient conceived and delivered viable twins. It is not known whether premature ovarian insufficiency associated with BPES type I follows the same clinical course as idiopathic premature ovarian insufficiency. In patients with BPES type I who present with infertility, ovarian stimulation with gonadotropins may be a reasonable therapeutic option.
- 28 February 2014
- Published by Wiley in Clinical Endocrinology
- Vol. 81 (3) , 418-425
Luteal phase dynamics of follicle‐stimulating and luteinizing hormones in obese and normal weight women
Summary: Objectives: Female obesity is a state of relative hypogonadotrophic hypogonadism. The aim of this study is to examine gonadotrophin secretion and response to gonadotrophin‐releasing hormone (GnRH) in the luteal phase of the menstrual cycle and to investigate the pharmacodynamics and pharmacokinetics of endogenous and exogenous luteinizing hormone (LH) in obese women.Design: Participants underwent a luteal phase frequent blood sampling study. Endogenous LH pulsatility was observed, gonadotrophin‐releasing hormone (GnRH) was given in two weight‐based doses, and GnRH antagonist was administered followed by recombinant LH.Patients: Regularly menstruating obese (n = 10) and normal weight (n = 10) women.Measurements: Endogenous hypothalamic‐pituitary function (as measured by LH pulsatility), pituitary sensitivity (GnRH‐induced LH secretion), pharmacodynamics of endogenous LH and pharmacokinetics of exogenous LH were compared between the obese and normal weight groups.Results: There were no statistically significant differences in endogenous LH pulsatility or pituitary responses to two weight‐based doses of GnRH between the obese and normal weight women. There were no differences in the pharmacodynamics of endogenous LH or the pharmacokinetics of exogenous LH between the groups. FSH dynamics did not differ between the groups throughout the study.Conclusions: The relative hypogonadotrophic hypogonadism of obesity cannot be explained by differences in LH and FSH luteal phase dynamics or differences in endogenous LH pharmacodynamics or exogenous LH pharmacokinetics.
- 28 February 2014
- Published by Wiley in Clinical Endocrinology
- Vol. 81 (3) , 418-425
Luteal phase dynamics of follicle‐stimulating and luteinizing hormones in obese and normal weight women
Summary: Objectives: Female obesity is a state of relative hypogonadotrophic hypogonadism. The aim of this study is to examine gonadotrophin secretion and response to gonadotrophin‐releasing hormone (GnRH) in the luteal phase of the menstrual cycle and to investigate the pharmacodynamics and pharmacokinetics of endogenous and exogenous luteinizing hormone (LH) in obese women.Design: Participants underwent a luteal phase frequent blood sampling study. Endogenous LH pulsatility was observed, gonadotrophin‐releasing hormone (GnRH) was given in two weight‐based doses, and GnRH antagonist was administered followed by recombinant LH.Patients: Regularly menstruating obese (n = 10) and normal weight (n = 10) women.Measurements: Endogenous hypothalamic‐pituitary function (as measured by LH pulsatility), pituitary sensitivity (GnRH‐induced LH secretion), pharmacodynamics of endogenous LH and pharmacokinetics of exogenous LH were compared between the obese and normal weight groups.Results: There were no statistically significant differences in endogenous LH pulsatility or pituitary responses to two weight‐based doses of GnRH between the obese and normal weight women. There were no differences in the pharmacodynamics of endogenous LH or the pharmacokinetics of exogenous LH between the groups. FSH dynamics did not differ between the groups throughout the study.Conclusions: The relative hypogonadotrophic hypogonadism of obesity cannot be explained by differences in LH and FSH luteal phase dynamics or differences in endogenous LH pharmacodynamics or exogenous LH pharmacokinetics.
- 4 January 2014
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 31 (3) , 355-362
Altered microRNA and gene expression in the follicular fluid of women with polycystic ovary syndrome
To determine if microRNAs are differentially expressed in the follicular fluid of women with PCOS compared to fertile oocyte donors and identify associated altered gene expression. Women undergoing IVF who met Rotterdam criteria for PCOS or who were fertile oocyte donors were recruited from a private IVF center. Individual follicle fluid was collected at the time of oocyte retrieval. MicroRNA analysis was performed using microarray and validated using real-time PCR on additional samples. Potential gene targets were identified and their expression analyzed by real time PCR. Microarray profiling of human follicular fluid revealed expression of 235 miRNAs, 29 were differentially expressed between the groups. Using PCR validation, 5 miRNAs (32, 34c, 135a, 18b, and 9) showed significantly increased expression in the PCOS group. Pathway analysis revealed genes involved in insulin regulation and inflammation. Three potential target genes were found to have significantly decreased expression in the PCOS group (interleukin 8, synaptogamin 1, and insulin receptor substrate 2). MicroRNAs are differentially expressed in the follicular fluid of women with PCOS when compared to fertile oocyte donors. There is also altered expression of potential target genes associated with the PCOS phenotype.
- 4 January 2014
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 31 (3) , 355-362
Altered microRNA and gene expression in the follicular fluid of women with polycystic ovary syndrome
To determine if microRNAs are differentially expressed in the follicular fluid of women with PCOS compared to fertile oocyte donors and identify associated altered gene expression. Women undergoing IVF who met Rotterdam criteria for PCOS or who were fertile oocyte donors were recruited from a private IVF center. Individual follicle fluid was collected at the time of oocyte retrieval. MicroRNA analysis was performed using microarray and validated using real-time PCR on additional samples. Potential gene targets were identified and their expression analyzed by real time PCR. Microarray profiling of human follicular fluid revealed expression of 235 miRNAs, 29 were differentially expressed between the groups. Using PCR validation, 5 miRNAs (32, 34c, 135a, 18b, and 9) showed significantly increased expression in the PCOS group. Pathway analysis revealed genes involved in insulin regulation and inflammation. Three potential target genes were found to have significantly decreased expression in the PCOS group (interleukin 8, synaptogamin 1, and insulin receptor substrate 2). MicroRNAs are differentially expressed in the follicular fluid of women with PCOS when compared to fertile oocyte donors. There is also altered expression of potential target genes associated with the PCOS phenotype.
The correlation between self-reported and measured height, weight, and BMI in reproductive age women
- 15 October 2011
- Published by Wolters Kluwer Health in Postgraduate Obstetrics & Gynecology
- Vol. 31 (19) , 1-5
Eating Disorders in the Obstetrics and Gynecology Population
- 15 October 2011
- Published by Wolters Kluwer Health in Postgraduate Obstetrics & Gynecology
- Vol. 31 (19) , 1-5
Eating Disorders in the Obstetrics and Gynecology Population